Compugen to Unveil COM701 Phase 1 Trials Analysis at ESMO 2025 in Berlin
Compugen Set to Present at ESMO 2025
Compugen Ltd., a prominent player in the field of cancer immunotherapy and known for its innovative use of predictive computational drug target discovery, announced its participation at the upcoming European Society for Medical Oncology (ESMO) 2025 congress, which is scheduled for October 17-21, 2025, in Berlin, Germany.
The company will showcase a pooled analysis from three Phase 1 clinical trials evaluating the efficacy of COM701, a promising candidate designed to treat patients with platinum-resistant ovarian cancer. This analysis is significant as it includes data from both monotherapy and combination therapy approaches, which could potentially pave the way for new treatment protocols.
The poster presentation is titled "COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials", featuring insights from Dr. Oladapo Yeku representing Massachusetts General Hospital in Boston, MA. The session is anticipated to stir discussions and questions among oncologists and researchers, reflecting the excitement and potential of emerging therapies in tackling hard-to-treat cancer types.
Poster Presentation Details:
- - Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S.
- - Poster Number: 1196P
- - Date of Presentation: Saturday, October 18, 2025, from 12:00 to 12:45 CEST
In advance of the event, Compugen has committed to making the poster available on its website, ensuring that interested parties can access the data even if they are unable to attend the congress in person.
About Compugen
Compugen is headquartered in Holon, Israel, and is listed on the Nasdaq (CGEN) and the Tel Aviv Stock Exchange (CGEN). The company specializes in developing therapies for cancer through a unique AI-powered computational discovery platform called Unigen™. This platform aids in identifying novel drug targets and biological pathways for advanced immunotherapies.
Currently, Compugen has two products in Phase 1 development: COM701 and COM902, each targeting critical checkpoints in cancer treatment. COM701 is being positioned as a first-in-class anti-PVRIG antibody, while COM902 targets TIGIT and has the potential to be a best-in-class therapy for solid tumors.
In addition to their key candidates, Compugen's portfolio includes collaborations and licensing agreements aimed at advancing various immuno-oncology programs. Notably, Rilvegostomig, a bispecific antibody in Phase 3 development by AstraZeneca, showcases Compugen's capabilities in therapeutic innovations.
As the oncology community eagerly anticipates the findings presented at ESMO 2025, Compugen stands out with its focus not only on existing treatments but also on paving pathways for novel therapies that could ultimately change the outlook for patients battling cancer, particularly those facing the challenges of platinum-resistant ovarian cancer.
For further information about Compugen's innovative pipeline and research initiatives, visit www.cgen.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.